Celldex Therapeutics, Inc. — Director's Dealing 2008

Mar 18, 2008

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-03-07

Reporting Person: SCHALLER CHARLES R (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$8.16	2018-03-07	Common Stock (14882)		Direct